Afleveringen
-
David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.
-
Silke covers key aspects of the meeting, including surgery vs RT, genetic and somatic testing, PSMA imaging and 1st line triplet therapy.
-
Zijn er afleveringen die ontbreken?
-
Thomas Suter and Chuck Ryan discuss identification and management of cardiovascular disease for patients starting therapy for prostate cancer.
-
Thomas Zilli and Pierre Blanchard discuss this topic from Lugano.
-
Jason Efstathiou and Piet Ost discuss the data for and against this approach.
-
Alison Birtle describes adjuvant chemotherapy in bladder cancer.
-
Daniel Goldstein describes his work on this issue.
-
In this second part, Matt Galsky describes the OS signal data. We also look into the future.
-
Tom, Brian and Matt Galsky review the screening component of this study, presented at EAU24.
-
Michiel Van der Heijden explores the role of radiotherapy and other neoadjuvant and other neoadjuvant combinations to prevent the need for surgery.
-
FDA Deputy Oncology Director Dan Suzman described approaches to oncology trials. Tom asks 3 last questions which annoys Brian more than usual.
-
Tanya Dorff describes acapatamab, a prostate-specific membrane antigen (PSMA) CD3 bispecific engager.
-
Michael Lattanzi discusses treatment plans and research in the community.
-
Hans Hammers discusses trial design and patient selection in the adjuvant setting.
-
Vania Wisdom, editor of the Lancet, talks about approaches to cancer treatment and research in developing countries
-
David McDermott discusses melanoma and renal data. We never get to bladder or lung.
-
Dana Rathkopf describes phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer
-
Silke, Tom and Brian cover the bases.
- Laat meer zien